Lumos Diagnostics
Carlsbad
About Lumos Diagnostics
Lumos Diagnostics offers point-of-care diagnostic test devices and a comprehensive suite of services. Its proprietary products include FebriDx, a rapid fingerstick blood test that helps distinguish bacterial from non-bacterial infections, and ViraDx, a rapid test for detecting COVID-19, Influenza A, and Influenza B simultaneously. Its service offerings encompass end-to-end capabilities such as assay development, reader technology, app and cloud integration, contract manufacturing, medical affairs, and quality and regulatory support. The company’s assay development spans lateral flow, ELISA, and microfluidic platforms, supporting various specimen types and detection formats. Manufacturing operations include ISO 13485-certified production of reagents, test kits, and reader devices under controlled conditions, facilitating seamless design transfer and scalable output.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $62.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: asx:LDX
- Website: lumosdiagnostics.com
- Phone: +1 760 683 5374
Industries & Categories
Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/lumos-diagnostics-14822 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.